Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Researchers can use this data to optimize COA design or selection regardless of modality, target demographic, or indication, with potential positive effects on comparability, translatability, data quality, and the patient experience, as COAs and expectations about them converge on more straightforward and familiar structures and language
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
Supporting muscle health while on GLP-1 medications Preventing muscle loss while using Ozempic and other GLP-1 medications involves a multifaceted approach that prioritizes nutrition, exercise, and supplementation
The premium impact on all members This is the part of the story that often gets lost in the debate
